Oxbryta Class Action Lawsuit 2025 Guide: Eligibility, Settlements & Filing Steps
Written and reviewed by: Ashley MilanoLast Updated: August 28th, 2025Lawsuits allege that Oxbryta (voxelotor), a sickle cell disease drug manufactured by Global Blood Therapeutics and later acquired by Pfizer, caused wrongful deaths and serious complications, including increased vaso-occlusive crises (VOCs) and strokes. This guide explains who qualifies, the injuries alleged, recent lawsuit updates, and what to expect from upcoming trials.
Who Qualifies for an Oxbryta Lawsuit
- Patient or family member took Oxbryta (voxelotor) for sickle cell disease;
- Experienced serious complications, including vaso-occlusive crises, strokes, or wrongful death;
- Medical records confirm diagnosis and treatment;
- Within your state’s statute of limitations to file a claim.
Oxbryta Injuries & Risks
- Vaso-occlusive crises (VOCs)
- Stroke
- Worsening sickle cell complications
- Wrongful death
- Economic and emotional losses for families
Oxbryta Settlement Ranges & Factors
No settlements have been reached yet. Based on similar defective drug litigations, potential settlement values may vary depending on:
- Severity of complications: wrongful death cases may see higher payouts;
- Age of the patient: younger patients often yield higher claims;
- Medical costs and lost wages;
- Evidence of Pfizer/GBT’s knowledge of risks;
- Venue & jury history.
Disclaimer: Settlement ranges are educational only and not guarantees. Actual outcomes depend on case-specific facts.
Deadlines for Filing an Oxbryta Lawsuit
Deadlines vary by state (generally 2–3 years from injury or death). Some claims may be extended if the injury was not discovered until later. Speak with an attorney quickly to protect your rights.
Oxbryta Lawsuit Updates™
Last updated August 2025.
- July 23, 2025: New wrongful death lawsuit alleges Oxbryta caused fatal VOCs and lacked adequate warnings.
- July 13, 2025: North Carolina family files lawsuit in NY Supreme Court citing serious Oxbryta injuries.
- July 1, 2025: MDL consolidation still under discussion; volume of cases may determine timing.
- June 6, 2025: Tennessee widow sues Pfizer/GBT, alleging Oxbryta caused husband’s death after VOCs and stroke.
- May 9, 2025: First Oxbryta trial scheduled for August 16, 2027.
- April 16, 2025: California widow sues Pfizer and hospitals, citing wrongful death linked to Oxbryta.
- March 1, 2025: Federal judge schedules first Oxbryta trial for June 7, 2027.
- Feb 4, 2025: Study published in Blood questioned due to high dropout rate; concerns persist over efficacy/safety.
- Dec 3, 2024: Pfizer withdraws Oxbryta globally over safety/efficacy concerns.
- Nov 19, 2024: EMA recommends halting Oxbryta sales due to safety risks.
- Nov 9, 2024: New California lawsuit alleges Oxbryta caused VOCs, stroke, and severe complications.
We update this section monthly with MDL activity, notable filings, and verdicts.
How the Oxbryta Lawsuit Process Works
- Case review: attorney reviews Oxbryta use and injuries;
- Filing: claim filed in federal court or state court;
- Discovery: exchange of medical records and company documents;
- Trial prep: bellwether trials scheduled for 2027;
- Settlement or verdict: payouts may follow trial outcomes or negotiations.
Oxbryta Lawsuit FAQs
Why was Oxbryta withdrawn?
Pfizer withdrew Oxbryta from the global market in late 2024 after regulators raised concerns about safety, efficacy, and cost-effectiveness.
What injuries are linked to Oxbryta?
Reports include increased vaso-occlusive crises (VOCs), strokes, worsening sickle cell complications, and wrongful deaths.
When will settlements happen?
None yet. First bellwether trials are scheduled for 2027; settlements may follow trial outcomes or expert rulings.
Sources & Safety Data
- FDA — drug recalls & safety alerts
- EMA — European regulatory decisions
- Blood Journal — published Oxbryta studies
Latest News
Loading...
Latest News
Loading...
